Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They will be taking the ´ treatment ´ live on Skype or other type of filmed manner
what if the person who is in the trial does not take the medication but gives it to someone else is there a way to test the trial patients to make sure they have taken it or are they just asking them to video the themselves treating themselves?
More exposure in our local city paper https://twitter.com/dailyecho/status/1265357670912897025?s=19
I’m not convinced that SNG001 will contribute to a cytokine storm. Although there is evidence SARS-Cov-2 promotes it.
Miggy.....so many people fretting over a few weeks here. Yes we all want SNG to be a magic bullet for CóVID reading so many articles lately about the various lung disorders and in this article the inhalation medication/ tech market is massive ! Billions !!! So surely doing this by the numbers is the right approach ! SNG aren't a one trick CóVID pony https://pharmaphorum.com/views-and-analysis/inhalation-technology-future-effective-respiratory-treatments/
ok If we are only able to be used at the start of the treatment.
without risking contributing to a cytokine storm will the nhs or people pay for a treatment before they know how bad it's going to get? I'm thinking not. So we won't be a treatment for all of the people who get covid.
we might just be a treatment for at risk groups who come into contact with Covid.
That being said surely any at risk groups will get a vacination as standard when it comes out.
So we won't be looking at billions in market cap plus our standard % seems to be 17% of the final sale price.
Interesting statistic! 35 million Americans living with chronic lung conditions! We really do also need at the bigger picture here. https://www.uth.edu/news/story.htm?id=b7d188be-d8a8-459c-b6a6-65d7684e81a5
Needs to be converted into an RNS... could land one tomorrow or next day based on the press release? interim result of trials? suprised really that this was only a press release today....good news of course is that top media picked up on it instantly. Just wait for the big news... who knows where we could go very quicky.
I think we will target care homes.
Where is ShareSting?
I think we need Nolupus to balance us out a bit. He plays the devils advocate role very well. I used to think he(you) were a deramper but I don’t now.
Ghia,
Resident pessimist ?
That's a bit unfair because that's far from the truth :-)
Why should i always have the bad role ?
I would appreciate it if other intelligent, ´ genuine ´ people would look at the other side for a change and let me off the hook a bit :-)
I think this is quite positive on reflection, wrt the unblinding. I think that’s the end of the COPD trial. The trial size of 109 is sufficient I would think, at least it appears to be for COVID-19. They have done that for a very good reason. I think this is news actually and very good news. I went in again today at 51.6 and 50.65, I do hope I’m right!
Miggy , have you forgotten on purpose the alpha 2b nasal drops ?
Let me refresh your memory
https://www.trialsitenews.com/can-recombinant-human-interferon-alpha-1b-nasal-drops-protect-medical-staff-from-covid-19/
Having read the RNSs and CEO interview my take is that it may only be hospital data results that become available in July - CEO when asked about Home said ‘later in the summer’.....is that what others understand to be the case?
8 weeks away lets hope the share price holds ground around the 50p mark 40's could happen as peeps get bored of waiting
Little has changed really. It is looking likely the true value of SNG001 will be seen as an early intervention drug against the virus. It will be useful to see the comparison between the hospital data and the home trial data. This will give some indication to drop off effectiveness as days post infection go by. The aim is to get SNG001 into patients lungs within three days of infection in the home setting. As far as I know no other drug anywhere can be taken as an early preventative measure. Should this go on to be a success the demand will be huge. Governments will want to stockpile and care homes and the vulnerable will need it on hand too. SNG is a patient sit no doubt but i truly believe this will come good. Seriously hope so for the sick,company and PI's.
Nolupus - As the resident pessimist I was hoping for you to fill in the blanks
Personally I could only see scenarios that would require guess work as to the outcome of the trial.
I chose not to rise to your bait ref the "lady " comment.
Ghia ,
I said this morning that you were an intelligent lady , so you have given us two scenarios ... but missing 1 :-)
Nolupus - As an optimist one could argue:
COPD interim analysis required to ensure fair value in the event that the hospital trial is positive and a move for the company is made... or when brokering licensing deals.
As a realist I suspect they saw the opportunity to use the delay caused by Covid to gain access to the data early. Second bite at the cherry to guard against inconclusive or unfavourable Hospital trial data. Risk management.
As a pessimist - *insert answer here*
Ghia - with trial designs as far as I'm aware the Synairgen process is as per normal.
Ghia,
It's just a side issue which will have to be adressed in a P3 trial :-)
The major question on today's news is elsewhere ... waiting on the debate which we have only touched on ...COPD .. and the need for interim results to confirm or infirm what ??
Nolupus - I was just trying to drill down to the crux of your objections I was hoping you had some information that you could share ref trial design that would spell out black and white why it was an issue.
As it transpires it's an opinion and we are all entitled to opinions so I won't press you further on it.
Ghia @ Today 15:51,
I understand and agree it won't make a significant difference. The objective for cro-sponsor is to minimise bias, but research suggests that it won't be reduced to zero - based on numerous companies - it's not uncommon as far as I'm aware for cro and sponsors to interact.
Ghia,
I have given my opinion so let's move on ...
What has been decided is in place now